High lung deposition of 99m Tc-labelled ciclesonide administered via HFA-MDI to asthma patients Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004
Slow particle dissolution may limit lung absorption of inhaled pharmaceuticals in the lungs Source: Eur Respir J 2006; 28: Suppl. 50, 210s Year: 2006
Greater esterification and retention of budesonide in the airways and lung as compared to ciclesonide after repeated intratracheal administration in vivo Source: Eur Respir J 2004; 24: Suppl. 48, 345s Year: 2004
Relationship between the inhaled and pulmonary absorbed dose of budesonide and mometasone furoate: A study in the isolated perfused rat lung Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Comparison of systemic bioavailability of two formulations of budesonide nebulized suspension in healthy subjects Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
Pharmacokinetics and pharmacodynamics of beclomethasone dipropionate and formoterol combination after inhalation using a new dry powder inhaler Source: Eur Respir J 2007; 30: Suppl. 51, 350s Year: 2007
A novel tool for the assessment of pulmonary disposition of dry powder aerosols; the isolated and perfused rat lung exposed to budesonide, formoterol and terbutaline Source: Eur Respir J 2007; 30: Suppl. 51, 352s Year: 2007
High doses of inhaled formoterol have less systemic effect in asthmatic children than high doses of inhaled terbutaline Source: Eur Respir J 2003; 22: Suppl. 45, 534s Year: 2003
Hydrofluoroalkane beclomethasone dipropionate extra fine aerosol efficacy response at reduced dose compared to other inhaled corticosteroid treatment regimens Source: Eur Respir J 2001; 18: Suppl. 33, 70s Year: 2001
The anti-inflammatory effect of budesonide 800 μg/day via Easyhaler® compared with the same dose of budesonide via Turbuhaler® in adult asthmatics Source: Eur Respir J 2001; 18: Suppl. 33, 337s Year: 2001
Concentrations of ciclesonide and its metabolites in the human lung after inhalation of 1280 μg ciclesonide Source: Eur Respir J 2006; 28: Suppl. 50, 212s Year: 2006
Lung bioavailability of beclometasone dipropionate and formoterol fumarate fixed dose combination administered using a pMDI or a novel DPI: NEXThaler® Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
Montelukast plus inhaled budesonide versus double dose inhaled budesonide in nonasthmatic eosinophilic bronchitis Source: Annual Congress 2011 - Asthma: control and treatment Year: 2011
Lung deposition distribution in astmatic patients of inhaled steroids when inhaled at the same time or 15 minutes after formoterol Source: Eur Respir J 2004; 24: Suppl. 48, 502s Year: 2004
Comparison of medium dose inhaled beclomethasone dipropionate (BDP) and low dose inhaled BDP plus sustained-release theophylline in the treatment of patients with moderate persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 42s Year: 2002
Salmeterol pharmacokinetics following a 50-mcg dose by dry powder oral inhalation to healthy volunteers Source: Annual Congress 2012 - Phenotypes and mechanisms of treatment of asthma Year: 2012
Gamma-scintigraphic evaluation of the delivered dose, lung deposition rate and distribution pattern of 99m Tc-labelled tiotropium via dry powder inhaler Source: Eur Respir J 2003; 22: Suppl. 45, 475s Year: 2003
A submicron suspension of budesonide improves the mass of ICS delivered during early nebulization Source: Eur Respir J 2006; 28: Suppl. 50, 712s Year: 2006
Lung deposition of fluticasone propionate/formoterol administered via a breath-triggered inhaler Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017
Tiotropium dose emission is influenced by the inhalation flow and the recommended two inhalations for each dose Source: Eur Respir J 2005; 26: Suppl. 49, 125s Year: 2005